Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) insider Jason R. Kelly sold 98,562 shares of Ginkgo Bioworks stock in a transaction on Friday, November 18th. The stock was sold at an average price of $2.17, for a total transaction of $213,879.54. Following the transaction, the insider now directly owns 20,623,653 shares of the company’s stock, valued at $44,753,327.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ginkgo Bioworks Price Performance
DNA stock opened at $1.98 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.67 and a current ratio of 11.71. The business has a 50-day moving average price of $2.71 and a 200 day moving average price of $2.82. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $1.94 and a 1-year high of $12.48.
Analyst Ratings Changes
Several analysts have recently weighed in on the company. BTIG Research decreased their target price on Ginkgo Bioworks to $4.00 in a research report on Thursday, November 17th. Morgan Stanley assumed coverage on Ginkgo Bioworks in a research report on Tuesday, October 4th. They set an “equal weight” rating and a $5.00 target price for the company. Finally, Raymond James decreased their target price on Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating for the company in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Ginkgo Bioworks currently has an average rating of “Hold” and a consensus target price of $5.91.
Institutional Trading of Ginkgo Bioworks
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.